GÉTICA 2021

34 VII FORO DE I nmunología Traslacional e INMUNOTERAPIA DEL CÁNCER REFERENCES 1. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related ad- verse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. 2. Griffin G, Shenoi S, Hughes GC. Hemophagocytic lympho- histiocytosis: An update on pathogenesis, diagnosis, and therapy. Best Practice & Research Clinical Rheumatology 2020;34:101515. 3. Rodríguez Pérez Á, Campillo-Davo D, Van Tendeloo VFI, Benítez-Ribas D. Cellular immunotherapy: a clinical state- of-the-art of a new paradigm for cancer treatment. Clin Transl Oncol 2020;22:1923-37. 4. Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocyt- ic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of Table I. List of case reports of hemophagocytic lymphohistiocytosis in oncological patients with immune checkpoint inhibitors (cont.) Immunotherapy Primary tumor Bone marrow biopsy Neurological symptoms Treatment Clinical outcomes Kalmuk J et al., 2020 Pembrolizumab Head and Neck + No Steroids and etoposide Improvement Takahasi et al., 2020 Pembrolizumab NSCLC + No Steroids Improvement Özdemir B et al., 2020 Ipilimumab and nivolumab Melanoma + No Steroids, tocili- zumab Improvement Dupré A et al., 2020 Pembrolizumab Pulmonary sarcomatoid carcinoma Not done No Steroids Death Dupré A et al., 2020 Ipilimumab + nivolumab Melanoma Not done No Steroids + etoposide + IVIG + Tocilizumab Improvement Dupré et al., 2020 Ipilimumab + nivolumab Melanoma + No Steroids + etoposide Death Dupré et al., 2020 Ipilimumab + nivolumab Melanoma - No Steroids Improvement Dupré et al., 2020 Ipilimumab + nivolumab Melanoma + No Steroids Improvement individual case safety reports. J Immunotherapy Cancer 2019;7:117. 5. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome: Score for Reactive He- mophagocytic Syndrome. Arthritis & Rheumatology 2014;66:2613–20. 6. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465-77. 7. Kumar B, AleemS, SalehH, Petts J, Ballas ZK. A Personalized Diagnostic and Treatment Approach for Macrophage Acti- vation Syndrome and Secondary Hemophagocytic Lym- phohistiocytosis in Adults. J Clin Immunol 2017;37(7):638- 43. DOI: 10.1007/s10875-017-0439-x.